A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Office of the Secretary of the Department of Health and Human Services relating to "Policy on Adhering to the Text of the Administrative Procedure Act".

The Senate's 50-50 vote on SJRES82 means the joint resolution to disapprove the HHS rule failed. This outcome maintains the status quo for the Office of the Secretary of the Department of Health and Human Services's "Policy on Adhering to the Text of the Administrative Procedure Act." This rule dictates how HHS interprets and applies the Administrative Procedure Act (APA) in its rulemaking. The failure to disapprove means HHS continues to operate under its stated policy, which emphasizes strict adherence to the APA's text. This prevents a potential period of uncertainty or re-evaluation of HHS's regulatory approach. Since the resolution failed, no new funding or specific contracts are initiated or terminated. The money trail remains unchanged, as this was a procedural vote on an existing policy. Companies operating within the healthcare sector, particularly those heavily influenced by HHS regulations, will continue to navigate the regulatory environment as it has been defined by HHS's policy. This includes pharmaceutical companies, medical device manufacturers, and healthcare providers. Historical precedent for congressional disapproval of agency rules under the Congressional Review Act (CRA) shows varied market reactions depending on the rule's scope. For instance, in March 2017, Congress used the CRA to disapprove an FCC rule on internet privacy, leading to a slight uptick in advertising technology stocks like Facebook (now Meta Platforms, $META) and Google (now Alphabet, $GOOGL) as data collection restrictions were lifted. However, this HHS rule is procedural, not substantive, meaning its disapproval would have primarily affected the *process* of rulemaking rather than specific regulations. The lack of disapproval means no such process change occurs, thus no direct market reaction is anticipated. There are no specific winners or losers from this vote. All companies within the healthcare sector, including major pharmaceutical firms like Johnson & Johnson ($JNJ), Pfizer ($PFE), and Merck ($MRK), as well as health insurers like UnitedHealth Group ($UNH) and Elevance Health ($ELV), will continue to operate under the existing regulatory framework. The vote prevents a potential shift in how HHS develops and implements regulations, which could have introduced uncertainty. The timeline for HHS rulemaking remains consistent with its current policy. What happens next is that HHS continues to operate under its existing policy regarding the APA. No further legislative action is expected on this specific rule in the immediate future. The outcome reinforces the current regulatory environment for the healthcare sector.